Multi-omic profiling reveals early immunological indicators for identifying COVID-19 Progressors.

Area of Science:

• Immunology
• Genomics
• Proteomics

Background:

• Existing research on SARS-CoV-2 immune response primarily focuses on acute and post-acute phases.
• Understanding early immune dynamics is crucial for predicting disease trajectory.

Purpose of the Study:

• To identify molecular associations with longitudinal disease outcomes in the immediate post-diagnosis phase of SARS-CoV-2 infection.
• To compare multi-omic immune cell signatures between individuals progressing to severe disease and those with milder courses.

Main Methods:

• Multi-omic analyses (transcriptomic, epigenomic, proteomic) were performed on immune cells from approximately 160 participants.
• Comparison of immune cell composition, cytokine levels, and cell subset-specific signatures between progressors and non-progressors.

Main Results:

• Progressors exhibited higher levels of multiple cytokines, notably IL-6.
• Skewed blood monocyte subsets were observed, with a decrease in non-classical and intermediate monocytes in progressors.
• CD8+ T effector memory cells in progressors showed gene expression indicative of stronger T cell activation.

Conclusions:

• Early molecular differences in immune responses are associated with COVID-19 disease progression.
• Identified signatures provide a basis for developing prognostic biomarkers and informing interventional strategies for severe COVID-19.